1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
September 2005 in “Journal of Investigative Dermatology” Ferulic acid helps stabilize vitamins C and E for better skin protection from the sun, certain compounds may promote hair growth, atopic dermatitis patients have lower skin defense molecules, older men are more likely to get a type of skin cancer, and a substance called relaxin may prevent age-related skin thickening.
September 2025 in “Egyptian Journal of Dermatology and Venerology” Dermoscopy is crucial for diagnosing rare scalp tumors like trichofolliculoma.
11 citations
,
June 2010 in “Dermatologic surgery” The dual-wavelength laser system effectively reduces EFFC symptoms with minimal side effects.
September 2024 in “Cutis” Sunscreen use may increase the risk of frontal fibrosing alopecia.
9 citations
,
October 1947 in “The Lancet” 1 citations
,
November 1947 in “The Lancet”
34 citations
,
June 1990 in “British Journal of Dermatology” Etretinate treatment changed hair growth patterns in many patients.
15 citations
,
April 2001 in “Journal of Dermatological Science” KF19418 promotes hair growth similarly to minoxidil but is not better in live mice.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
28 citations
,
October 2010 in “Targeted Oncology” Trastuzumab may cause tufted hair folliculitis as a side effect.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
4 citations
,
June 2017 in “Annales de dermatologie et de vénéréologie” The study found that a specific type of hair loss is increasingly common in premenopausal women and can be effectively diagnosed and treated with various medications.
2 citations
,
January 2017 in “Journal of Cosmetics, Dermatological Sciences and Applications” TrichoTech™ may help hair growth and skin repair by increasing fibroblast growth and activity.
11 citations
,
January 1999 in “Dermatology” September 2017 in “BAUST Journal”
January 2026 in “SSRN Electronic Journal” Riboflavin with blue light speeds up hair dyeing, making it faster, safer, and long-lasting with less hair damage.
April 2014 in “Investigative Ophthalmology & Visual Science”
45 citations
,
January 1992 in “Dermatology” Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
2 citations
,
December 2018 Alopecia frontal fibrosante affects facial vellus hair and can be diagnosed with dermatoscopy.
21 citations
,
February 2013 in “Clinics in Dermatology” New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
39 citations
,
January 1977 in “Dermatology” The treatment cleared psoriasis in some patients but caused side effects in most.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.